Press Releases

Articles in this section

  • Gilead’s HCV drug sofosbuvir approved by the FDA but accessible for how many? Press Release – December 9 / Bangkok – Paris – Basel – London – New York

    On December 6, the U.S. Food and Drug Administration approved Gilead’s sofosbuvir (Sovaldi), an oral medication for the treatment of hepatitis C virus (HCV). Sofosbuvir and other direct-acting antivirals (DAAs) coming out of the drug development pipeline are more potent, have fewer side effects, (...) More

  • The time bomb is ticking…. Defuse hepatitis C, the viral time bomb! Press Release — July 25, 2013

    On the occasion of World Hepatitis Day (July 28), millions of people living with hepatitis C virus (HCV) and their advocates—Médecins du Monde (MdM), the International Network of People who Use Drugs (INPUD), Treatment Action Group (TAG), the Asia Pacific Network of People Living with HIV/AIDS (...) More